Mirum Pharmaceuticals (MEX:MIRM) Stock Based Compensation: MXN1,676 Mil (TTM As of Mar. 2026)


MEX:MIRM Mirum Pharmaceuticals Inc MEX:MIRM
46 GF Score
Price MXN1,256.12
GF Value MXN849.96
! 6 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Stock Based Compensation?

Mirum Pharmaceuticals MEX:MIRM 46 Stock Based Compensation is MXN1,676 Mil as of Mar. 2026. GuruFocus rates MEX:MIRM with a GF Score™ of 46/100 and a GF Value™ of MXN849.96. The stock has 6 warning signs investors should review.

Mirum Pharmaceuticals's Stock Based Compensation for the three months ended in Mar. 2026 was MXN653 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was MXN1,676 Mil.

Mirum Pharmaceuticals Stock Based Compensation Related Terms

Mirum Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Stock Based Compensation Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 473.61 526.53 594.49 1,010.33 1,286.04

Mirum Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 323.30 347.74 332.53 342.58 652.82
MEX:MIRM
46GF Score
Mirum Pharmaceuticals Inc MEX:MIRM
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,676 Mil.

What does a Stock Based Compensation of MXN1,676 Mil mean?
Mirum Pharmaceuticals (MEX:MIRM) has a Stock Based Compensation of MXN1,676 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Mirum Pharmaceuticals and its competitors.
Is Mirum Pharmaceuticals' Stock Based Compensation too high?
Mirum Pharmaceuticals' current Stock Based Compensation is MXN1,676 Mil. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Stock Based Compensation compare to RYTM and SYRE?
Mirum Pharmaceuticals' Stock Based Compensation of MXN1,676 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Stock Based Compensation is MXN1,676 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Stock Based Compensation of MXN1,676 Mil. The stock's GF Value™ is MXN849.96, compared to a current price of MXN1,256.12 — trading 47.8% above its estimated fair value. The current Stock Based Compensation is MXN1,676 Mil. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Stock Based Compensation is MXN1,676 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,256.12 is trading 47.8% above its estimated GF Value™ of MXN849.96.

Key valuation signals for MEX:MIRM:

  • Stock Based Compensation: MXN1,676 Mil
  • GF Value™: MXN849.96 vs. price of MXN1,256.12 (47.8% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score

Get the complete analysis for MEX:MIRM

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,256.12
Price
MXN849.96
GF Value